Research Topics
| Chantal CsajkaSummaryAffiliation: Centre Hospitalier Universitaire Vaudois Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patientsC Csajka
Division of Clinical Pharmacology, University Hospital, CHUV, Lausanne, Switzerland
Eur J Clin Pharmacol 57:723-7. 2001....- Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteersChantal Csajka
Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
Clin Pharmacokinet 41:137-52. 2002..To compare the pharmacokinetic and pharmacodynamic characteristics of angiotensin II receptor antagonists as a therapeutic class... - Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionChantal Csajka
Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
Clin Pharmacol Ther 73:20-30. 2003.... 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavirRubin Lubomirov
Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
Pharmacogenet Genomics 20:217-30. 2010....
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infectionSara Colombo
Division of Clinical Pharmacology and Toxicology, University Hospital, CHUV, Lausanne 1011, Switzerland
Antimicrob Agents Chemother 50:3801-8. 2006..This population pharmacokinetic model, together with therapeutic drug monitoring and Bayesian dosage adaptation, can be helpful in the selection and adaptation of ATV doses...- Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individualsRubin Lubomirov
Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
Pharmacogenet Genomics 23:9-18. 2013..To identify the potential impact of genetic and non-genetic factors involved in ETV metabolism, we carried out a two-step pharmacogenetics-based population pharmacokinetic study in HIV-1 infected individuals... - Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursAmina Haouala
Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
Br J Clin Pharmacol 75:1007-18. 2013..In this study, free and total imatinib concentrations were measured to establish a model allowing the confident prediction of imatinib free concentrations based on total concentrations and plasma proteins measurements... - Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsMona Arab-Alameddine
Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
Antimicrob Agents Chemother 56:2959-66. 2012..Owing to the very large variability, trough drug levels might be very low under the standard dosing regimen, raising the question of a potential relevance of therapeutic drug monitoring of RAL in some situations... - Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virusChantal Csajka
Division of Clinical Pharmacology, University Hospital, CHUV, Beaumont 633, Lausanne 1011, Switzerland
Antimicrob Agents Chemother 48:3226-32. 2004..The high interpatient pharmacokinetic variability represents an argument for therapeutic drug monitoring... - Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levelsVerena Gotta
Division of Clinical Pharmacology and Toxicology, Laboratory Department, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
Clin Pharmacokinet 51:187-201. 2012..In practice, however, blood sampling for TDM is often not performed at trough. The corresponding measurement is thus only remotely informative about C(min) exposure... - Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapyThierry Buclin
Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
PLoS ONE 6:e18578. 2011..We developed rules to guide frequency of CD4 cell count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from the Swiss HIV Cohort Study... - In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 functionJulia Di Iulio
Institute of Microbiology Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
Pharmacogenet Genomics 19:300-9. 2009..We hypothesize that genetic variability in this gene may contribute to the particularly high, unexplained variability in EFV exposure in individuals with limited CYP2B6 function... - Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomesVerena Gotta
Division of Clinical Pharmacology, Service of Biomedicine, Department of Laboratories, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland
Ther Drug Monit 35:150-67. 2013..For future research, external PPK model validation or meta-model development should be considered... - Benchmarking therapeutic drug monitoring software: a review of available computer toolsAline Fuchs
Division of Clinical Pharmacology, Service of Biomedicine, Department of Laboratory, Hôpital de Beaumont, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1011, Lausanne, Switzerland
Clin Pharmacokinet 52:9-22. 2013..Computer-assisted TDM is gaining growing interest and should further improve, especially in terms of information system interfacing, user friendliness, data storage capability and report generation... - Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agentsMargalida Rotger
Institute of Microbiology and University Hospital, Lausanne, Switzerland
Curr HIV/AIDS Rep 3:118-25. 2006..Despite the negative perception of genetic research among the general public, this type of investigation is now widely accepted by concerned parties: patients, relatives, and study volunteers... - Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patientsSandrine Ostermann
Multidisciplinary Oncology Center, Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Clin Cancer Res 10:3728-36. 2004..The AUC(CSF)/AUC(plasma) ratio was 20%. Systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety... - Pharmacokinetic-pharmacodynamic modelling: history and perspectivesChantal Csajka
Department of Biopharmaceutical Sciences, University of California, San Francisco, CA, USA
J Pharmacokinet Pharmacodyn 33:227-79. 2006.... - Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjectsChantal Csajka
Department of Biopharmaceutical Sciences and Biostatistics, University of California, San Francisco, 94143, USA
J Pharmacol Exp Ther 313:647-57. 2005..The increase in heart rate due to CHF3381 was 0.0055 bpm/micro(g l-1). CHF3381 produces a concentration-dependent decrease in DHPG plasma concentrations, whose magnitude increased after multiple twice-a-day regimens for 14 days... - ADME pathway approach for pharmacogenetic studies of anti-HIV therapyRubin Lubomirov
Institute of Microbiology, University Hospital and University of Lausanne, Bugnon 48, 1011 Lausanne, Switzerland
Pharmacogenomics 8:623-33. 2007..This review compiles information for future analysis of the role of specific genes/variants in the exposure and response to antiretroviral therapy to generate a ranked list of new genetic variants for future studies...